Hansen, A. R., Probst, S., Beauregard, J., Viglianti, B. L., Michalski, J. M., Tagawa, S. T., . . . Fleshner, N. E. (2025). Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: Dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial. Frontiers in oncology, 14, 1483953. https://doi.org/10.3389/fonc.2024.1483953
Citace podle Chicago (17th ed.)Hansen, Aaron R., et al. "Initial Clinical Experience with [177Lu]Lu-PNT2002 Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer: Dosimetry, Safety, and Efficacy from the Lead-in Cohort of the SPLASH Trial." Frontiers in Oncology 14 (2025): 1483953. https://doi.org/10.3389/fonc.2024.1483953.
Citace podle MLA (9th ed.)Hansen, Aaron R., et al. "Initial Clinical Experience with [177Lu]Lu-PNT2002 Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer: Dosimetry, Safety, and Efficacy from the Lead-in Cohort of the SPLASH Trial." Frontiers in Oncology, vol. 14, 2025, p. 1483953, https://doi.org/10.3389/fonc.2024.1483953.